Home - DECISION

News

26 January 2023

New Masterclass Video of Agustín Albillos

In this new Masterclass video on YouTube, DECISION consortium member Prof. Dr. Agustín Albillos Martínez (SERMAS) provides an overview of the effects of low molecular weight heparin (LMWH) in cirrhosis, including the mode of action of anti-coagulants, followed by the pathophysiological basis for the long-term use of anticoagulation in cirrhosis as well as the experience with anticoagulants in the clinic. The masterclass took place in the realm of the 4th General Assembly (GA) Meeting on 19th October 2023 in Madrid, Spain, as part of DECISION’s training programme for the project’s early-career scientists (ECS). View all Masterclass videos here.

More news

Events

19 - 21 October 2022

4th General Assembly (GA) meeting in Madrid

The 4th GA meeting of DECISION took place from 19-21 October 2022 in Madrid. The meeting was a great success with the first day devoted to paper writing: on that day, 12 meetings took place to discuss and progress on 7 different papers with more than 20 people. On the second day, we extensively discussed the specifics of our upcoming COMBAT-Trial as well as our brand new and refined animal models of ACLF. The third day was devoted to multi-omics analyses, bioinformatics and machine learning as well as an update on the newly developed tools and checklists for ethics and data protection and the health economics studies planned in DECISION. We thank our Scientific Advisory Board members for their valuable feedback to improve the quality of our studies.

More events

Twitter

Tweets by Decision4Liver

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.